Umbellatine

Colorectal Adenoma

Jing-yuan Fang, MD, Ph. DSmall moleculePhase 2/3Active

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 46/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Colorectal Adenoma cohort.

Asset / Sponsor	Phase	Rating
Mesalamine UMC Utrecht	Phase 2	B
Celecoxib University of Alabama at Birmingham	Phase 2	B
muc1 peptide-poly-iclc vaccine National Cancer Institute (NCI)	Phase 2	CCC
Linaclotide Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2	CCC
Aspirin University of Edinburgh	Phase 2	CCC

View all 11 →

Same molecule, other indications

Umbellatine is also rated in:

inherited lipid metabolism disorderActive

BBB

Indicative · Phase 4

72 / 100

abdominal obesity-metabolic syndromeActive

BB

Indicative · Phase 4

69 / 100

metabolic dysfunction-associated steatotic liver diseaseActive

BB

Indicative · Phase 4

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.